NCT07868939Phase 3Recruiting

Oral VK2735 for Weight Management in Adults With Type 2 Diabetes Mellitus Phase 3 (SUNRISE 2)

Study sponsor: Viking Therapeutics, Inc. · VKTX

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2028-10Estimated
Enrollment · participants560Estimated
Source updated2026-11-16Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters

· 1 field changed

Recruitment status changed

Before: Not yet recruiting. After: Recruiting.

Check registry source

· 1 field changed

Main study measure wording changed

Text changed; whether the study measures changed has not been verified. Saved text may be shortened.

Before: Measure: Percent change in body weight for participants with type 2 diabetes mellitus receiving VK2735 orally once daily Description: To demonstrate that VK2735 27.5mg, 35mg, and 55mg daily oral (each dose separately) is superior to placebo for percent change in body weight from baseline to week 68 Time frame: 68 weeks. After: Measure: Percent change in body weight for participants with type 2 diabetes mellitus receiving VK2735 orally once daily Description: To demonstrate that VK2735 daily oral is superior to placebo for percent change in body weight from baseline to week 68 Time frame: 68 weeks.

Check registry source